Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicity.

Sengupta P, Basu S, Soni S, Pandey A, Roy B, Oh MS, Chin KT, Paraskar AS, Sarangi S, Connor Y, Sabbisetti VS, Kopparam J, Kulkarni A, Muto K, Amarasiriwardena C, Jayawardene I, Lupoli N, Dinulescu DM, Bonventre JV, Mashelkar RA, Sengupta S.

Proc Natl Acad Sci U S A. 2012 Jul 10;109(28):11294-9. doi: 10.1073/pnas.1203129109. Epub 2012 Jun 25.

2.

Harnessing structure-activity relationship to engineer a cisplatin nanoparticle for enhanced antitumor efficacy.

Paraskar AS, Soni S, Chin KT, Chaudhuri P, Muto KW, Berkowitz J, Handlogten MW, Alves NJ, Bilgicer B, Dinulescu DM, Mashelkar RA, Sengupta S.

Proc Natl Acad Sci U S A. 2010 Jul 13;107(28):12435-40. doi: 10.1073/pnas.1007026107. Epub 2010 Jun 23.

3.

Rationally designed oxaliplatin-nanoparticle for enhanced antitumor efficacy.

Paraskar A, Soni S, Roy B, Papa AL, Sengupta S.

Nanotechnology. 2012 Feb 24;23(7):075103. doi: 10.1088/0957-4484/23/7/075103.

4.

Supramolecular nanoparticles that target phosphoinositide-3-kinase overcome insulin resistance and exert pronounced antitumor efficacy.

Kulkarni AA, Roy B, Rao PS, Wyant GA, Mahmoud A, Ramachandran M, Sengupta P, Goldman A, Kotamraju VR, Basu S, Mashelkar RA, Ruoslahti E, Dinulescu DM, Sengupta S.

Cancer Res. 2013 Dec 1;73(23):6987-97. doi: 10.1158/0008-5472.CAN-12-4477. Epub 2013 Oct 11.

5.

Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.

Marzano C, Bettio F, Baccichetti F, Trevisan A, Giovagnini L, Fregona D.

Chem Biol Interact. 2004 Jun 30;148(1-2):37-48.

PMID:
15223355
6.

Rationally engineered polymeric cisplatin nanoparticles for improved antitumor efficacy.

Paraskar A, Soni S, Basu S, Amarasiriwardena CJ, Lupoli N, Srivats S, Roy RS, Sengupta S.

Nanotechnology. 2011 Jul 1;22(26):265101. doi: 10.1088/0957-4484/22/26/265101. Epub 2011 May 17.

7.

Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.

Hadinoto K, Sundaresan A, Cheow WS.

Eur J Pharm Biopharm. 2013 Nov;85(3 Pt A):427-43. doi: 10.1016/j.ejpb.2013.07.002. Epub 2013 Jul 17. Review.

PMID:
23872180
8.

Gold nanoparticles for the improved anticancer drug delivery of the active component of oxaliplatin.

Brown SD, Nativo P, Smith JA, Stirling D, Edwards PR, Venugopal B, Flint DJ, Plumb JA, Graham D, Wheate NJ.

J Am Chem Soc. 2010 Apr 7;132(13):4678-84. doi: 10.1021/ja908117a.

9.

Pharmacokinetics, biodistribution and in vivo efficacy of cisplatin loaded poly(L-glutamic acid)-g-methoxy poly(ethylene glycol) complex nanoparticles for tumor therapy.

Yu H, Tang Z, Zhang D, Song W, Zhang Y, Yang Y, Ahmad Z, Chen X.

J Control Release. 2015 May 10;205:89-97. doi: 10.1016/j.jconrel.2014.12.022. Epub 2014 Dec 18.

PMID:
25529533
10.

Micellar nanoparticle formation via electrostatic interactions for delivering multinuclear platinum(II) drugs.

Xiao H, Stefanick JF, Jia X, Jing X, Kiziltepe T, Zhang Y, Bilgicer B.

Chem Commun (Camb). 2013 May 25;49(42):4809-11. doi: 10.1039/c3cc39119a.

PMID:
23595166
11.

Synthesis and in vitro and in vivo antitumor activity of a series of trans platinum antitumor complexes.

Kelland LR, Barnard CF, Evans IG, Murrer BA, Theobald BR, Wyer SB, Goddard PM, Jones M, Valenti M, Bryant A, et al.

J Med Chem. 1995 Aug 4;38(16):3016-24.

PMID:
7636864
12.

Intraperitoneal delivery of platinum with in-situ crosslinkable hyaluronic acid gel for local therapy of ovarian cancer.

Cho EJ, Sun B, Doh KO, Wilson EM, Torregrosa-Allen S, Elzey BD, Yeo Y.

Biomaterials. 2015 Jan;37:312-9. doi: 10.1016/j.biomaterials.2014.10.039. Epub 2014 Oct 24.

13.

Synthesis, cytotoxicity and antitumor activity of platinum(II) complexes of cyclopentanecarboxylic acid hydrazide.

Kushev D, Gorneva G, Taxirov S, Spassovska N, Grancharov K.

Biol Chem. 1999 Nov;380(11):1287-94.

PMID:
10614821
14.

Synthesis, characterization, and biological evaluation of new tetrazole-based platinum(II) and palladium(II) chlorido complexes--potent cisplatin analogues and their trans isomers.

Serebryanskaya TV, Yung T, Bogdanov AA, Shchebet A, Johnsen SA, Lyakhov AS, Ivashkevich LS, Ibrahimava ZA, Garbuzenco TS, Kolesnikova TS, Melnova NI, Gaponik PN, Ivashkevich OA.

J Inorg Biochem. 2013 Mar;120:44-53. doi: 10.1016/j.jinorgbio.2012.12.001. Epub 2012 Dec 13.

PMID:
23305964
15.
16.

Enhanced toxicity of cisplatin with chemosensitizer phenethyl isothiocyanate toward non-small cell lung cancer cells when delivered in liposomal nanoparticles.

Yang YT, Shi Y, Jay M, Di Pasqua AJ.

Chem Res Toxicol. 2014 Jun 16;27(6):946-8. doi: 10.1021/tx5001128. Epub 2014 May 20.

PMID:
24836554
17.

Synthesis and antitumor activity of a series of [2-substituted-4,5-bis(aminomethyl)-1,3-dioxolane]platinum(II) complexes.

Kim DK, Kim G, Gam J, Cho YB, Kim HT, Tai JH, Kim KH, Hong WS, Park JG.

J Med Chem. 1994 May 13;37(10):1471-85.

PMID:
8182706
18.

Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.

Hoch U, Lynch J, Sato Y, Kashimoto S, Kajikawa F, Furutani Y, Silverman JA.

Cancer Chemother Pharmacol. 2009 Jun;64(1):53-65. doi: 10.1007/s00280-008-0850-3. Epub 2008 Oct 19.

PMID:
18931998
19.

In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers.

Alberts DS, Fanta PT, Running KL, Adair LP Jr, Garcia DJ, Liu-Stevens R, Salmon SE.

Cancer Chemother Pharmacol. 1997;39(6):493-7.

PMID:
9118460
20.

cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.

Raynaud FI, Boxall FE, Goddard PM, Valenti M, Jones M, Murrer BA, Abrams M, Kelland LR.

Clin Cancer Res. 1997 Nov;3(11):2063-74.

Supplemental Content

Support Center